New cancer drug enters first human trials
NCT ID NCT05394675
Summary
This was the first human study testing an experimental drug called DS-9606a in people with advanced solid tumors, including ovarian, lung, and pancreatic cancers. The main goals were to find a safe dose and understand how the body processes the drug. The study was terminated early and involved 88 adults whose cancer had progressed despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Florida Cancer Specialists & Research Institute, LLC
Fort Myers, Florida, 33916, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
SCRI at HealthONE
Denver, Colorado, 80216, United States
-
Sarah Cannon Research Institute UK
London, W1G 6AD, United Kingdom
-
The Royal Marsden NHS Trust
Sutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.